Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.
2.

A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis.

Luckner SR, Liu N, am Ende CW, Tonge PJ, Kisker C.

J Biol Chem. 2010 May 7;285(19):14330-7. doi: 10.1074/jbc.M109.090373. Epub 2010 Mar 3.

3.

Time-dependent diaryl ether inhibitors of InhA: structure-activity relationship studies of enzyme inhibition, antibacterial activity, and in vivo efficacy.

Pan P, Knudson SE, Bommineni GR, Li HJ, Lai CT, Liu N, Garcia-Diaz M, Simmerling C, Patil SS, Slayden RA, Tonge PJ.

ChemMedChem. 2014 Apr;9(4):776-91. doi: 10.1002/cmdc.201300429. Epub 2014 Mar 11.

4.

Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.

He X, Alian A, Ortiz de Montellano PR.

Bioorg Med Chem. 2007 Nov 1;15(21):6649-58. Epub 2007 Aug 15.

5.
6.

Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.

Matviiuk T, Rodriguez F, Saffon N, Mallet-Ladeira S, Gorichko M, de Jesus Lopes Ribeiro AL, Pasca MR, Lherbet C, Voitenko Z, Baltas M.

Eur J Med Chem. 2013;70:37-48. doi: 10.1016/j.ejmech.2013.09.041. Epub 2013 Oct 2.

PMID:
24140915
7.

Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.

Lu H, Tonge PJ.

Acc Chem Res. 2008 Jan;41(1):11-20. doi: 10.1021/ar700156e. Review.

PMID:
18193820
8.

A structural and energetic model for the slow-onset inhibition of the Mycobacterium tuberculosis enoyl-ACP reductase InhA.

Li HJ, Lai CT, Pan P, Yu W, Liu N, Bommineni GR, Garcia-Diaz M, Simmerling C, Tonge PJ.

ACS Chem Biol. 2014 Apr 18;9(4):986-93. doi: 10.1021/cb400896g. Epub 2014 Mar 10.

9.
10.

Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.

Oliveira JS, de Sousa EH, de Souza ON, Moreira IS, Santos DS, Basso LA.

Curr Pharm Des. 2006;12(19):2409-24. Review.

PMID:
16842188
11.

Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis.

Tonge PJ, Kisker C, Slayden RA.

Curr Top Med Chem. 2007;7(5):489-98. Review.

PMID:
17346194
12.

Rational design of InhA inhibitors in the class of diphenyl ether derivatives as potential anti-tubercular agents using molecular dynamics simulations.

Kamsri P, Koohatammakun N, Srisupan A, Meewong P, Punkvang A, Saparpakorn P, Hannongbua S, Wolschann P, Prueksaaroon S, Leartsakulpanich U, Pungpo P.

SAR QSAR Environ Res. 2014;25(6):473-88. doi: 10.1080/1062936X.2014.898690. Epub 2014 Apr 30.

PMID:
24785640
13.

Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis.

Oliveira JS, Pereira JH, Canduri F, Rodrigues NC, de Souza ON, de Azevedo WF Jr, Basso LA, Santos DS.

J Mol Biol. 2006 Jun 9;359(3):646-66. Epub 2006 Apr 21.

PMID:
16647717
14.

Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid.

Parikh SL, Xiao G, Tonge PJ.

Biochemistry. 2000 Jul 4;39(26):7645-50.

PMID:
10869170
15.

Recent progress in the identification and development of InhA direct inhibitors of Mycobacterium tuberculosis.

Lu XY, You QD, Chen YD.

Mini Rev Med Chem. 2010 Mar;10(3):181-92. Review.

PMID:
20408801
16.

Discovery of novel InhA reductase inhibitors: application of pharmacophore- and shape-based screening approach.

Kumar UC, Bvs SK, Mahmood S, D S, Kumar-Sahu P, Pulakanam S, Ballell L, Alvarez-Gomez D, Malik S, Jarp S.

Future Med Chem. 2013 Mar;5(3):249-59. doi: 10.4155/fmc.12.211.

PMID:
23464516
17.

Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.

Rozwarski DA, Grant GA, Barton DH, Jacobs WR Jr, Sacchettini JC.

Science. 1998 Jan 2;279(5347):98-102.

18.

Direct inhibitors of InhA are active against Mycobacterium tuberculosis.

Manjunatha UH, S Rao SP, Kondreddi RR, Noble CG, Camacho LR, Tan BH, Ng SH, Ng PS, Ma NL, Lakshminarayana SB, Herve M, Barnes SW, Yu W, Kuhen K, Blasco F, Beer D, Walker JR, Tonge PJ, Glynne R, Smith PW, Diagana TT.

Sci Transl Med. 2015 Jan 7;7(269):269ra3. doi: 10.1126/scitranslmed.3010597.

19.

Cross-docking study on InhA inhibitors: a combination of Autodock Vina and PM6-DH2 simulations to retrieve bio-active conformations.

Stigliani JL, Bernardes-GĂ©nisson V, Bernadou J, Pratviel G.

Org Biomol Chem. 2012 Aug 21;10(31):6341-9. doi: 10.1039/c2ob25602a. Epub 2012 Jun 29.

PMID:
22751934
20.

Synthesis and biological activities of triazole derivatives as inhibitors of InhA and antituberculosis agents.

Menendez C, Gau S, Lherbet C, Rodriguez F, Inard C, Pasca MR, Baltas M.

Eur J Med Chem. 2011 Nov;46(11):5524-31. doi: 10.1016/j.ejmech.2011.09.013. Epub 2011 Sep 16.

PMID:
21944473
Items per page

Supplemental Content

Write to the Help Desk